Unnamed stage
Corporate / CVC · 3 deals
SPRIM Global Investments
Singapore
Disclosed deals
Every published round SPRIM Global Investments took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
| Company | Stage | Announced | Amount | Role | Alongside | Sources |
|---|---|---|---|---|---|---|
| Vaxxas | Venture debt | Aug 2025 | $40m | Participant | Startup Daily (Fri 29 Aug 2025), SmartCompany, Startup Daily (Tue 26 Aug 2025), Business News Australia | |
| Vaxxas | Series D+ | Aug 2025 | $49m | Lead | Startup Daily (Tue 23 Dec 2025), SmartCompany (Tue 23 Dec 2025), Startup Daily (Tue 14 Oct 2025), Cut Through Venture, Startup Daily (Fri 29 Aug 2025), SmartCompany (Fri 29 Aug 2025), Startup Daily (Tue 26 Aug 2025), Business News Australia | |
| Prota Therapeutics | Series A | Jan 2024 | $31.6m | Lead | SmartCompany (Fri 26 Apr 2024), SmartCompany (Wed 10 Apr 2024), Forbes Australia, Business News Australia, SmartCompany (Fri 19 Jan 2024), Startup Daily |
Portfolio
Companies SPRIM Global Investments has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| Prota Therapeutics | Jan 2024, Series A | 1 | 1 | |
| Vaxxas | Aug 2025, Venture debt | 2 | 1 |
Funds
Fund closes reported for SPRIM Global Investments, as distinct from the investments it has made.
Portfolio companies acquired
Companies SPRIM Global Investments has backed that another company then bought. An exit for the holding, not a deal SPRIM Global Investments did.
People
| Name | Role | Sources |
|---|---|---|
| Michael Shleifer | Co-founder and Managing Partner | Startup Daily, Business News Australia, sprim.com |
Coverage
Stories naming SPRIM Global Investments. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
7 deals
Five Aussie startups that raised $95.45 million this week
Weekly roundup detailing five Australian raises: Vaxxas' Series D plus debt facility amid executive changes, Skutopia's growth round, Send Payments' backing and CEO change, Apate.ai's seed, and Coursebox's seed.
Also Startup Daily·SmartCompany·Australian FinTech·Dealroom·Startup Daily
2 deals
Vaccination biotech Vaxxas raises $49 million Series D, cuts C-suite amid broader layoffs
Australian biotech Vaxxas secured a Series D plus a debt facility while overhauling leadership: a new chair, founding CEO shifting to an advisory role, and CFO made redundant amid job cuts.
Also Business News Australia·SmartCompany·Cut Through Venture·Startup Daily·Startup Daily·SmartCompany·Startup Daily
Series D+
~$90m
Vaxxas secures ~A$90 million in funding to commercialise needle-free vaccination delivery technology
Vaxxas announced a roughly A$90m financing — Series D equity led by SPRIM Global Investments plus debt — to advance its needle-free vaccine patch, alongside leadership changes including a new chair.
4 deals
Four Aussie startups that have raised $94.5 million already in January
Roundup of January 2024 funding: Futurerent, Prota Therapeutics, National Renewable Network and Getmee together secured $94.5 million across debt, equity and a government grant, with investor details for each deal.
Series A
$32m
Allergies biotech startup Prota Therapeutics innoculated with $32 million in Series A1 raise
Prota Therapeutics, a Melbourne biotech, has secured $32 million in equity and debt ahead of a Phase 3 trial of its peanut allergy therapy, with Singapore's SPRIM Global Investments leading the round.
Also SmartCompany·SmartCompany·SmartCompany·Business News Australia·Forbes Australia